Merus Fuels Next-Generation Cancer Therapies: $300M Investment in Revolutionary Biclonics® Technology

Merus is thrilled to announce that we have successfully raised €300,000,000 in our latest funding round, marking a significant milestone in our mission to revolutionize cancer treatment. This pivotal investment will accelerate the development of our best-in-class therapeutics designed to treat and potentially cure cancer patients by harnessing the innovative Biclonics® format. Biclonics® are engineered to simultaneously target tumors on multiple fronts—activating the immune system to attack cancer cells and directly inhibiting the pathways essential for tumor cell growth and survival. By leveraging this dual-action approach, we aim to deliver therapies that not only improve patient outcomes but also provide hope where traditional treatments have fallen short. With our headquarters located in The Netherlands, complemented by our US office and a robust global network of collaborators, Merus is uniquely positioned to make a meaningful impact in the oncology field. This latest funding injection reinforces our commitment to advancing cutting-edge bispecific antibody therapies through rigorous clinical trials and research efforts. Over the past decade, we have seen promising progress, with several candidate drugs now in clinical trials and our pioneering approach gaining recognition on global platforms. For current and prospective team members, this is an unparalleled opportunity to join a forward-thinking company dedicated to career growth and meaningful contributions to cancer research. We are excited to drive forward innovation and therapeutic breakthroughs that have the potential to transform the lives of countless patients worldwide. To learn more about our groundbreaking work and future initiatives, please visit our website at www.merus.nl, and join us on our journey to redefine cancer care.